ClinicalTrials.gg
TerminatedNCT03116529NEXISUpdated Nov 5, 2026Results posted

Neoadjuvant Durvalumab and Tremelimumab Plus Radiation for High Risk Soft-Tissue Sarcoma

A Phase 1/2 interventional study of Combination Radiation, Immunotherapy, Surgery in Soft Tissue Sarcoma, sponsored by University of Maryland, Baltimore. Terminated at 3 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-05.

Sponsored by University of Maryland, Baltimore · Phase 1/2, Interventional, and Treatment

How we know · 7 judgments

Why this study was terminated
Limited Accrual
Updated Nov 5, 2026Results postedStudy documents posted+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
22
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 958 studies in Sarcoma with a site in United States — 153 open to participants now, 242 under way, 4 of them phase 3. Sarcoma · United States.

Enrollment
536th of 800
22 · median 35
Started
2017
with 38 others
Phase 1/2
112 of 958
28 open now
Registered
598th of 958
by date

Among the 958 studies in Sarcoma with a site in United States, this one is the 536th largest by enrollment of the 800 interventional ones that give a count, is one of 39 that started in 2017, is one of 112 in phase 1/2, and was the 598th registered.

Sarcoma

1,610 studies on the registry are indexed under Sarcoma; 367 are open to participants now.

Browse Sarcoma studies →

Open to participants now

153 of the 958 studies in Sarcoma with a site in United States are open now. Recruiting first, the newest first:

148 more — sign in →

All 153 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 302 Sarcoma studies recruiting now, 192 (64%) set no upper age limit and 83 (27%) stop at 75 or younger; 94 take children under 18; 12 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 958 studies in Sarcoma with a site in United States, or all of them as a file.
02

Study summary

Chemotherapy is controversial for soft tissue sarcoma that has not yet metastasized. Surgery and radiation are effective for local control, but there are no highly effective interventions to prevent metastatic spread of soft tissue sarcoma. Immunotherapy has shown promise in other types of cancer. Combining two types of immunotherapy agents with preoperative radiation may help the immune system recognize the sarcoma and stimulate an anti-tumor immune response.

Read the detailed description

The main purposes of this study are to evaluate the safety, tolerability, and efficacy of Durvalumab and Tremelimumab in combination with radiation prior to surgical resection of high-risk soft tissue sarcoma in the pelvis and extremities.

Patients will receive the same radiation therapy and surgical care they would receive normally and with no change in timing or duration of each treatment. They will also receive two immunotherapy agents, Durvalumab and Tremelimumab, during radiation prior to surgery, and a single agent, Durvalumab, after surgery.

03

Conditions studied

  • Soft Tissue Sarcoma

Browse trials for

Keywords

  • Neoadjuvant
  • Soft Tissue Sarcoma
  • Immunotherapy
  • Checkpoint Inhibitor
  • PD-1 (Programmed Cell Death Protein 1)
  • PD-L1 (Programmed Death Ligand 1)
  • CTLA-4 (Cytotoxic T-Lymphocyte-Associated Protein 4)
  • Radiotherapy
  • Durvalumab
  • Tremelimumab
  • Surgery
  • Radiation
  • Combined
  • Preoperative
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Written
  • Willingness and ability to comply with the protocol for the duration of the study
  • confirmed intermediate or high grade adult-type soft tissue sarcoma
  • Location of tumor is trunk (non-retroperitoneal) or extremities
  • Tumor at least 5 cm in greatest dimension and deep to fascia, or locally recurrent, or , or have had prior inadequate resections
  • Judged as at least marginally resectable
  • (ECOG) performance status 0-1
  • Adequate normal organ and marrow function
  • Female subjects must be either of non- (i.e., by history: ≥60 years old and no menses for ≥1 year without an alternative medical cause; OR history of hysterectomy, OR history of bilateral tubal ligation, OR history of bilateral oophorectomy) or must have a negative serum pregnancy test upon study entry.
  • Females of who are sexually active with a non-sterilized male partner and non-sterilized male subjects who are sexually active with a female partner of childbearing potential must be willing to use 2 methods of effective from time of screening through 180 days after receipt of the final dose of Durvalumab + Tremelimumab combination therapy or 90 days after receipt of the final dose of Durvalumab Monotherapy, whichever is the longer time period.

Exclusion criteria

Exclusion Criteria:

  • Primarily bone-based sarcomas that can occur in the soft tissue such as: extra-skeletal Ewing sarcoma, extra-skeletal osteosarcoma, peripheral chordoma, extra-skeletal myxoid chondrosarcoma, and mesenchymal chondrosarcoma
  • Predominantly low-grade soft tissue sarcoma, such as solitary fibrous tumor / hemangiopericytoma, well-differentiated liposarcoma, dermatofibrosarcoma protuberans, Kaposi's sarcoma
  • Pediatric-type soft tissue sarcoma, such as rhabdomyosarcoma
  • Gastrointestinal stromal tumors (GIST)
  • Retroperitoneal soft tissue sarcoma
  • Patients with extra-pulmonary aside from lymph node involvement
  • Surgically unresectable primary lesion
  • Symptomatic or uncontrolled requiring concurrent treatment, inclusive of but not limited to surgery, radiation and/or .
  • Any previous treatment with an (programmed cell death protein-1), anti-PD-L1 (programmed death ligand 1) or anti-CTLA-4 (cytotoxic T-lymphocyte-associated protein 4) therapy, including Durvalumab and Tremelimumab
  • History of to Durvalumab or any
  • History of hypersensitivity to Tremelimumab or any excipient
  • History of hypersensitivity to the combination or comparator agent
  • History or clinically confirmed pneumonitis or interstitial lung disease
  • Receipt of the last dose of anti-cancer therapy (cytotoxic chemotherapy, immunotherapy, endocrine therapy, targeted therapy, biologic therapy, tumor embolization, monoclonal antibodies, other agent) ≤ 28 days prior to the first dose of study drug (28 days prior to the first dose of study drug for subjects who have received prior TKIs (tyrosine kinase inhibitors) [e.g., erlotinib, gefitinib and crizotinib] and within 6 weeks for nitrosourea or mitomycin C [If sufficient time has not occurred due to the schedule or PK properties of an agent, a longer wash-out period may be required])
  • Current or prior use of medication within 28 days before the first dose of durvalumab or tremelimumab, with the exceptions of intranasal and inhaled corticosteroids or systemic corticosteroids at physiological doses, which are not to exceed 10 mg/day of prednisone, or an equivalent corticosteroid
  • Any unresolved toxicity (>grade 2) from previous anti-cancer therapy. NOTE: Subjects with irreversible toxicity that is not reasonably expected to be exacerbated by the investigational product may be included (e.g., hearing loss, peripherally neuropathy)
  • Any prior immune-related adverse event (irAE) ≥ Grade 2 while receiving any previous immunotherapy agent, or any unresolved irAE > Grade 1
  • Active or prior documented disease within the past 2 years. NOTE: Subjects with vitiligo, Grave's disease, or psoriasis not requiring systemic treatment (within the past 2 years) are not excluded.
  • History of primary immunodeficiency
  • History of allogeneic organ transplant (e.g. solid organ/bone marrow transplant patients)
  • Uncontrolled intercurrent illness including, but not limited to:
  • Ongoing or active infections
  • Cardiac conditions, such as:
  • symptomatic congestive heart failure
  • uncontrolled hypertension
  • unstable angina pectoris
  • cardiac arrhythmia
  • Active peptic ulcer disease or gastritis
  • History of inflammatory bowel disease, ulcerative colitis or Crohn's Disease
  • Active bleeding diatheses
  • Any subject known to have evidence of acute or chronic or
  • Any subject known to have evidence of (HIV) or acquired immune deficiency syndrome (AIDS)
  • Uncontrolled seizures
  • Mean corrected for heart rate (QTc) ≥470 ms calculated from 3 (ECGs) using Fredericia's Correction
  • Known history of current or recent clinical diagnosis of tuberculosis (within three months prior to enrollment)
  • Active or prior documented inflammatory bowel disease (e.g., Crohn's disease, ulcerative colitis)
  • Any signs or symptoms of bowel obstruction within 28 days prior to study entry
  • History of
  • Receipt of within 30 days prior to study entry or within 30 days of receiving durvalumab or tremelimumab, or active infection
  • History of psychiatric illness/social situations that would limit compliance with study requirements or compromise the ability of the subject to give written
  • Any condition that, in the opinion of the investigator, would interfere with evaluation of study treatment or interpretation of patient safety or study results
  • Previously enrolled in the present study
  • Participation in another clinical study with an investigational product during the last 6 months
  • Previously enrolled in the present study
  • Involvement in the planning and/or conduct of the study (applies to both AstraZeneca staff and/or staff at the study site)
  • Female patients who are pregnant or breastfeeding or male or female patients of who are not willing to employ effective from screening to 180 days after the last dose of durvalumab + tremelimumab combination therapy or 90 days after the last dose of durvalumab monotherapy, whichever is the longer time period
Terms in these criteria, in plain language(24)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
22 participants (actual)

Study arms

  • Experimental
    Treatment

    Neoadjuvant Radiation plus Durvalumab and Tremelimumab Wide Surgical Resection Adjuvant Durvalumab

    Combination Product: Combination Radiation, Immunotherapy, Surgery

Interventions

  • Combination productCombination Radiation, Immunotherapy, Surgery

    Three doses of Durvalumab (1500 mg) and Tremelimumab (75 mg) given intravenously once every four weeks during radiotherapy prior to surgery. Radiation therapy delivered with a minimum dose of 50 Gy and 1.8-2 Gy per fraction. Bulky sarcomas, defined as \>10 cms in greatest dimension, receive a single 15 Gy fraction of high-dose spatially fractionated (GRID) radiation therapy within 1-3 days prior to radiation therapy Surgical resection is performed at least 5-8 weeks after cessation of radiotherapy and 4 weeks after completion of neoadjuvant immunotherapy. Patients with no evidence of disease following surgical resection receive four additional doses and patients with evidence of disease receive nine additional doses of Durvalumab (1500 mg IV) once every four weeks unless there is clear progression of disease.

This study also gives DurvalumabStudies of DurvalumabDurvalumab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record., TremelimumabStudies of TremelimumabTremelimumab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.. No intervention listed here names it: that was found by reading the record.

06

What researchers measure

Primary outcomes

  1. Toxicity: Number of Subjects Experiencing High-grade Toxicity

    high-grade toxicity experienced during the course of the study

    Time frame: 90 days after receipt of final dose of Durvalumab monotherapy or 180 days after receipt of final dose of combination Durvalumab/Tremelimumab, whichever is longer

  2. Histopathologic Response

    Number of subjects with an excellent response on histopathologic examination of the surgically removed tumor

    Time frame: At time of surgery

Secondary outcomes

  1. Overall Survival Rate

    Number of patients still alive

    Time frame: Two years after start of treatment

07

Results

Posted Nov 5, 2026

Participant flow

Participant flow — Overall Study
MilestoneNeoadjuvant Radiation Plus Durvalumab and Tremelimumab Wide Surgical Resection Adjuvant Durvalumab
Started22
Completed18
Not completed4

Outcome measures

PrimaryToxicity: Number of Subjects Experiencing High-grade Toxicity

high-grade toxicity experienced during the course of the study

Time frame:
90 days after receipt of final dose of Durvalumab monotherapy or 180 days after receipt of final dose of combination Durvalumab/Tremelimumab, whichever is longer
Reported as:
Number · participants
Toxicity: Number of Subjects Experiencing High-grade Toxicity
participantsTreatment
Toxicity: Number of Subjects Experiencing High-grade Toxicity10
PrimaryHistopathologic Response

Number of subjects with an excellent response on histopathologic examination of the surgically removed tumor

Time frame:
At time of surgery
Reported as:
Count of participants · Participants
Histopathologic Response
ParticipantsTreatment
Histopathologic Response12
SecondaryOverall Survival Rate

Number of patients still alive

Time frame:
Two years after start of treatment
Reported as:
Count of participants · Participants
Overall Survival Rate
ParticipantsTreatment
Overall Survival Rate12

Adverse events

Collected over 2 years. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Neoadjuvant Durvalumab and Tremelimumab Plus Radiation6/18 (33.3%)3/18 (16.7%)16/18 (88.9%)
Most frequent serious events
Most frequent serious events
EventNeoadjuvant Durvalumab and Tremelimumab Plus Radiation
Serious Adverse EventsGeneral disorders3/18
Most frequent other events
Most frequent other events
EventNeoadjuvant Durvalumab and Tremelimumab Plus Radiation
Adverse Events for this study were monitored/assessed in such a manner that the specific Adverse EveGeneral disorders16/18

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Treatment
<=18 years0
Between 18 and 65 years15
>=65 years3
Age, Continuous
Age, Continuous(years)Treatment
Mean52 (20 to 84)
Sex: Female, Male
Sex: Female, Male(Participants)Treatment
Female7
Male11
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Treatment
American Indian or Alaska Native0
Asian1
Native Hawaiian or Other Pacific Islander0
Black or African American3
White14
More than one race0
Unknown or Not Reported0
Region of Enrollment
Region of Enrollment(Participants)Treatment
United States18
08

Study locations

3 sites
  • University of Arizona
    Tucson, Arizona 85724, United States
  • University of Maryland Medical Center, Greenebaum Comprehensive Cancer Center
    Baltimore, Maryland 21201, United States
  • Allegheny General Hospital
    Pittsburgh, Pennsylvania 15212, United States
09

References and documents

Publications

  • Ng VY, Sahlani MN, Fogel JD, Chiu AK, Kallen ME, Davis D, Snider J, Regine W, Bentzen SM, Sausville E. Results of an Integrated Phase I/II Prospective Clinical Trial (NEXIS) for Neoadjuvant Anti-PD-L1 (Durvalumab) and Anti-CTLA-4 (Tremelimumab) With Radiation for High-Risk Soft-Tissue Sarcoma of the Trunk and Extremities. Cureus. 2024 Oct 22;16(10):e72119. doi: 10.7759/cureus.72119. eCollection 2024 Oct. PubMed 39575028 ↗
  • Vatner R, James CD, Sathiaseelan V, Bondra KM, Kalapurakal JA, Houghton PJ. Radiation therapy and molecular-targeted agents in preclinical testing for immunotherapy, brain tumors, and sarcomas: Opportunities and challenges. Pediatr Blood Cancer. 2021 May;68 Suppl 2:e28439. doi: 10.1002/pbc.28439. Epub 2020 Aug 22. PubMed 32827353 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Undecided

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2017 to primary completion in Jun 2024, 84 months.

Results were first posted in Nov 2026, 2 years 4 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 12, 2017
First posted
Apr 17, 2017
StartActual
Jun 21, 2017
Primary completionActual
Jun 21, 2024
CompletionActual
Jun 21, 2024
Results first posted
Nov 5, 2026
Last update
Nov 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted
posted Nov 5, 2026
Primary outcomes
1 edited
What changed in the outcomes
  • EditedToxicity: Number of subjects experiencing highSubjects Experiencing High-grade toxicityToxicityTime frame: 90 days after receipt of final dose of Durvalumab monotherapy or 180 days after receipt of final dose of combination Durvalumab/Tremelimumab, whichever is longer
Nov 5, 2026
Publications
1 publication citing this study linked from PubMed, e.g. PubMed 39575028 ↗
Nov 5, 2026
Secondary outcomes
7 removed, 1 description edited
What changed in the outcomes
  • RemovedOverall Survival RateTime frame: Five years after start of treatment
  • RemovedDisease-Specific Survival RateTime frame: Two years after start of treatment
  • RemovedDisease-Specific Survival RateTime frame: Five years after start of treatment
  • RemovedRelapse-Free Survival RateTime frame: Two years after start of treatment
  • RemovedRelapse-Free Survival RateTime frame: Five years after start of treatment
  • RemovedRadiologic Response To TreatmentTime frame: At time of surgery
  • RemovedRadiologic Response To TreatmentTime frame: At time of surgery
  • DescriptionOverall Survival Rate: how it is measured was reworded
Nov 5, 2026
Show all 1 update
  1. Nov 5, 2026
    Results posted
    Publications 1 publication citing this study linked from PubMed, e.g. PubMed 39575028 ↗
    Primary outcomes 1 edited
    What changed in the outcomes
    • EditedToxicity: Number of subjects experiencing highSubjects Experiencing High-grade toxicityToxicityTime frame: 90 days after receipt of final dose of Durvalumab monotherapy or 180 days after receipt of final dose of combination Durvalumab/Tremelimumab, whichever is longer
    Secondary outcomes 7 removed, 1 description edited
    What changed in the outcomes
    • RemovedOverall Survival RateTime frame: Five years after start of treatment
    • RemovedDisease-Specific Survival RateTime frame: Two years after start of treatment
    • RemovedDisease-Specific Survival RateTime frame: Five years after start of treatment
    • RemovedRelapse-Free Survival RateTime frame: Two years after start of treatment
    • RemovedRelapse-Free Survival RateTime frame: Five years after start of treatment
    • RemovedRadiologic Response To TreatmentTime frame: At time of surgery
    • RemovedRadiologic Response To TreatmentTime frame: At time of surgery
    • DescriptionOverall Survival Rate: how it is measured was reworded
    + 2 other changes: verification date and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT03116529
Collaborators
AstraZeneca, University of Arizona, West Penn Allegheny Health System
Responsible party
Vincent Ng (Assistant Professor, University of Maryland, Baltimore) — Principal investigator
First posted
Apr 17, 2017
Start date
Jun 21, 2017
Primary completion
Jun 21, 2024
Completion
Jun 21, 2024
Results posted
Nov 5, 2026
Last update
Nov 5, 2026

Study contacts

Vincent Y. Ng, MD
principal investigator · University of Maryland Medical Center, Greenebaum Comprehensive Cancer Center

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Durvalumab · Tremelimumab

Start the discussion